Antoinette R. Tan
About
Antoinette R. Tan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Antoinette R. Tan has authored 140 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Oncology, 66 papers in Pulmonary and Respiratory Medicine and 39 papers in Molecular Biology. Recurrent topics in Antoinette R. Tan's work include Cancer Treatment and Pharmacology (42 papers), Advanced Breast Cancer Therapies (39 papers) and HER2/EGFR in Cancer Research (36 papers). Antoinette R. Tan is often cited by papers focused on Cancer Treatment and Pharmacology (42 papers), Advanced Breast Cancer Therapies (39 papers) and HER2/EGFR in Cancer Research (36 papers). Antoinette R. Tan collaborates with scholars based in United States, Spain and Belgium. Antoinette R. Tan's co-authors include Sandra M. Swain, Michael Reiß, Bruce J. Dezube, Geoffrey I. Shapiro, Jay A. Berzofsky, Frank J. Hsu, Thomas Olencki, Donald P. Lawrence, Vassiliki Karantza and Hope S. Rugo and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.
In The Last Decade
Antoinette R. Tan
136 papers receiving 5.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Antoinette R. Tan United States | 36 | 4.0k | 1.8k | 1.5k | 999 | 766 | 140 | 5.4k | ||
| Petri Bono Finland | 44 | 3.9k 1.0× | 2.7k 1.5× | 2.4k 1.6× | 1.6k 1.6× | 1.3k 1.6× | 156 | 7.5k | ||
| Ferry A.L.M. Eskens Netherlands | 43 | 2.9k 0.7× | 2.6k 1.5× | 1.5k 1.0× | 1.2k 1.2× | 461 0.6× | 161 | 6.4k | ||
| Daniele Generali Italy | 42 | 3.1k 0.8× | 2.5k 1.4× | 1.7k 1.1× | 2.1k 2.1× | 475 0.6× | 232 | 6.2k | ||
| Carolyn D. Britten United States | 36 | 3.0k 0.8× | 2.4k 1.4× | 1.5k 1.0× | 624 0.6× | 606 0.8× | 96 | 5.6k | ||
| Giampaolo Bianchini Italy | 34 | 3.9k 1.0× | 2.4k 1.4× | 1.4k 0.9× | 2.3k 2.3× | 1.1k 1.5× | 139 | 6.5k | ||
| Otto Metzger United States | 30 | 3.2k 0.8× | 1.4k 0.8× | 1.4k 0.9× | 1.7k 1.7× | 432 0.6× | 117 | 4.8k | ||
| Roman K. Thomas Germany | 37 | 3.1k 0.8× | 2.6k 1.5× | 2.0k 1.3× | 1.1k 1.1× | 707 0.9× | 95 | 5.7k | ||
| Niels Reinmuth Germany | 43 | 5.0k 1.3× | 2.9k 1.6× | 2.9k 1.9× | 1.5k 1.5× | 851 1.1× | 196 | 7.9k | ||
| Juanita Lopez United Kingdom | 28 | 2.6k 0.7× | 1.9k 1.1× | 1.3k 0.8× | 821 0.8× | 1.2k 1.6× | 144 | 4.9k | ||
| E. Gabriela Chiorean United States | 42 | 4.7k 1.2× | 2.1k 1.2× | 1.5k 1.0× | 1.7k 1.7× | 1.7k 2.2× | 209 | 7.1k |
Countries citing papers authored by Antoinette R. Tan
Since
Specialization
Citations
This map shows the geographic impact of Antoinette R. Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antoinette R. Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antoinette R. Tan more than expected).
Fields of papers citing papers by Antoinette R. Tan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Antoinette R. Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antoinette R. Tan. The network helps show where Antoinette R. Tan may publish in the future.
Co-authorship network of co-authors of Antoinette R. Tan
This figure shows the co-authorship network connecting the top 25 collaborators of Antoinette R. Tan. A scholar is included among the top collaborators of Antoinette R. Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antoinette R. Tan. Antoinette R. Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Heeke, Arielle L., Andrew Elliott, Chad Livasy, et al.. (2025). Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers. JCO Precision Oncology. 9(9). e2300719–e2300719.
2.
Hamilton, Erika, Hyo S. Han, Anne F. Schott, et al.. (2023). 390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial. Annals of Oncology. 34. S344–S344.
3.
Sammons, Sarah, Andrew Elliott, Romualdo Barroso‐Sousa, et al.. (2023). Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer. Frontiers in Oncology. 13. 1235902–1235902.
4.
Swain, Sandra M., Antoinette R. Tan, Luca Gianni, et al.. (2022). Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. European Journal of Cancer. 178. 70–81.
5.
Hamilton, E.P., Charles L. Shapiro, Valentina Boni, et al.. (2022). 162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer. Annals of Oncology. 33. S196–S196.
6.
Pegram, Mark D., Erika Hamilton, Antoinette R. Tan, et al.. (2021). First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. Molecular Cancer Therapeutics. 20(8). 1442–1453.
7.
Tan, Antoinette R., Gail S. Wright, Anu Thummala, et al.. (2021). Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study. Clinical Cancer Research. 28(4). 629–636.
8.
Tan, Antoinette R., Seock‐Ah Im, André Mattar, et al.. (2020). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. The Lancet Oncology. 22(1). 85–97.
9.
El‐Deiry, Wafik S., Richard M. Goldberg, Heinz‐Josef Lenz, et al.. (2019). The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA A Cancer Journal for Clinicians. 69(4). 305–343.
10.
Rugo, Hope S., Jean‐Pierre Delord, Seock‐Ah Im, et al.. (2018). Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer. Clinical Cancer Research. 24(12). 2804–2811.
11.
Tan, Antoinette R., Rebecca Feldman, James T. Symanowski, et al.. (2017). Molecular profiling comparison of breast cancer subtypes in young women and older women.. Journal of Clinical Oncology. 35(15_suppl). 11581–11581.
12.
Lacouture, Mario E., John C. Morris, Donald P. Lawrence, et al.. (2015). Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008). Cancer Immunology Immunotherapy. 64(4). 437–446.
13.
Abraham, Jame, André Robidoux, Antoinette R. Tan, et al.. (2015). Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9. Breast Cancer Research and Treatment. 152(2). 399–405.
14.
Jankowitz, Rachel C., Jame Abraham, Antoinette R. Tan, et al.. (2013). Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study. Cancer Chemotherapy and Pharmacology. 72(6). 1205–1212.
15.
Liang, Hongyan & Antoinette R. Tan. (2011). PARP Inhibitors. Current Breast Cancer Reports. 3(1). 44–54.
16.
Tan, Antoinette R., Eric H. Rubin, Dale E. Shuster, et al.. (2009). Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors. Clinical Cancer Research. 15(12). 4213–4219.
17.
Burris, Howard A., Andreas du Bois, Afshin Dowlati, et al.. (2009). Abstract A6: Pazopanib combination with paclitaxel and carboplatin in patients with advanced solid tumors and gynecological cancers: Results of two phase I studies. Molecular Cancer Therapeutics. 8(12_Supplement). A6–A6.
18.
Fetterly, Gerald J., Thaddeus H. Grasela, Jeffrey W. Sherman, et al.. (2008). Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Neutropenia during Phase I Development of Liposome-Entrapped Paclitaxel. Clinical Cancer Research. 14(18). 5856–5863.
19.
Tan, Antoinette R., Seth M. Steinberg, Allyson L. Parr, Dao Nguyen, & Sherry X. Yang. (2007). Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment. Annals of Oncology. 19(1). 185–190.
20.
Yang, Sherry, Richard Simon, Antoinette R. Tan, Diana Nguyen, & Sandra M. Swain. (2005). Gene Expression Patterns and Profile Changes Pre- and Post-Erlotinib Treatment in Patients with Metastatic Breast Cancer. Clinical Cancer Research. 11(17). 6226–6232.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Petri Bono Breakdown of academic impact, for papers by Ferry A.L.M. Eskens Breakdown of academic impact, for papers by Daniele Generali Breakdown of academic impact, for papers by Carolyn D. Britten Breakdown of academic impact, for papers by Giampaolo Bianchini Breakdown of academic impact, for papers by Otto Metzger Breakdown of academic impact, for papers by Roman K. Thomas Breakdown of academic impact, for papers by Niels Reinmuth Breakdown of academic impact, for papers by Juanita Lopez Breakdown of academic impact, for papers by E. Gabriela Chiorean